|
Bridgehead Consulting Assists Innovative
Medical Device Company, Tyrell Inc
March 2008
Bridgehead International
recently completed an independent due diligence study on Tyrell
Inc. as part of a fundraising programme. Tyrell Inc. is a
medical technology company focused on the development of medical
devices for the treatment of skin lesions. Comprised of experts
from both the medical and consumer products industries, Tyrell
develops and market new, non-prescription medical devices
based on its proprietary ClearPoint™ Technology. The first
of these is Zeno™, for over-the-counter treatment of acne.
Zeno™ was given FDA clearance as a Class II medical device
in June 2005. A CE mark in Europe was granted in 2006 and
the product is also approved in Canada, Japan and a number
of other Asian markets. Further products based on the ClearPoint™
technology are in development.
Paul Tufano, Chief
Financial Officer of Tyrell said:
"As
an international medical device company which has launched
multiple devices spanning numerous indications, we often have
difficulty finding a consultancy firm that has the depth of
technical expertise and market resources to assess the landscape
with which we work.
"Our
engagement of Bridgehead has proven to be very valuable to
the growth and operation of our business. Their assessment
of the competitive landscape, our product strategy and the
intellectual property environment has driven many important
changes to the way we have managed the success of our business.
"We
look forward to our next engagement with Bridgehead and their
very professional team."
|
